Tissue study for ER-positive breast cancer
Part of Cancer, Skin clinical trials.
This study looks at stored tumor tissue from people with a certain type of breast cancer to see if certain markers can help predict how well hormone therapy works. It may help doctors better understand which treatments are best for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had breast cancer that is ER-positive and HER2-negative
- You received hormone therapy (like tamoxifen or an aromatase inhibitor) after surgery
- Your tumor tissue from surgery is stored and available for testing
- Your medical records are complete with treatment history and follow-up information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects small samples of breast cancer tissue during routine biopsies to learn more about how breast cancer behaves. It may help doctors understand the cancer better, but it does not test a new treatment.
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
Hear when a new Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.